Glaxosmi. Pharma Cash flow Statement
Figures in Rs cr
Consolidated Cash Flow Results
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
No of Months
12
12
12
12
12
12
Profit Before Tax
959.00
841.00
2,475.00
723.00
647.00
653.00
Adjustment
-45.00
-40.00
-1,636.00
-25.00
13.00
-31.00
Changes In working Capital
61.00
-45.00
119.00
45.00
44.00
-4.00
Cash Flow after changes in Working Capital
975.00
755.00
959.00
743.00
704.00
618.00
Cash Flow from Operating Activities
582.00
484.00
810.00
577.00
490.00
409.00
Cash Flow from Investing Activities
8.00
807.00
-405.00
418.00
-56.00
-153.00
Cash Flow from Financing Activities
-561.00
-1,543.00
-524.00
-695.00
-427.00
-358.00
Net Cash Inflow / Outflow
29.00
-251.00
-119.00
300.00
6.00
-102.00
Opening Cash & Cash Equivalents
34.00
286.00
405.00
104.00
98.00
201.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
64.00
34.00
286.00
405.00
104.00
98.00
Compare Cash Flow Results of Glaxosmi. Pharma
Figures in Rs cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
959.8
2399.36
-1,440.00
-60.00%
Adjustment
-45.13
212.2
-257.00
-121.27%
Changes In working Capital
61.02
20.42
41.00
198.82%
Cash Flow after changes in Working Capital
975.69
2631.98
-1,656.00
-62.93%
Cash Flow from Operating Activities
582.02
2152.45
-1,570.00
-72.96%
Cash Flow from Investing Activities
8.71
-2080.52
2,088.00
100.42%
Cash Flow from Financing Activities
-561.5
5.27
-566.00
-10754.65%
Net Cash Inflow / Outflow
29.23
77.19
-48.00
-62.13%
Opening Cash & Cash Equivalents
34.94
304.82
-270.00
-88.54%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
64.17
382.01
-318.00
-83.20%
Cash Flow - Snapshot (Consolidated) - Mar'24
YoY Growth in year ended Mar 2024 is 20.19% vs -40.27% in Mar 2023
Mar'24
Mar'23
Change(%)
Cash Flow from Operating Activities
582.02
484.23
20.19%